{"id":729,"date":"2026-07-20T09:50:55","date_gmt":"2026-07-20T09:50:55","guid":{"rendered":"https:\/\/onestepblowmachine.com\/?p=729"},"modified":"2026-07-20T09:50:55","modified_gmt":"2026-07-20T09:50:55","slug":"how-injection-stretch-blow-moulding-machines-produce-pp-bottles-for-autoclave-sterilized-pharmaceuticals","status":"publish","type":"post","link":"https:\/\/onestepblowmachine.com\/nl\/sollicitatie\/how-injection-stretch-blow-moulding-machines-produce-pp-bottles-for-autoclave-sterilized-pharmaceuticals\/","title":{"rendered":"How Injection Stretch Blow Moulding Machines Produce PP Bottles for Autoclave-Sterilized Pharmaceuticals"},"content":{"rendered":"
\n
\n

Pharmaceutical & Medical Packaging \u00b7 Technical Guide<\/p>\n

A technical guide to the role of the spuitrekblaasvormmachine<\/strong> in pharmaceutical PP bottle production \u2014 covering polypropylene’s autoclave compatibility, manufacturing structure, GMP compliance frameworks, and machine selection for pharmaceutical packaging producers worldwide.<\/p>\n<\/div>\n

<\/p>\n

\n

Autoclave sterilization remains the gold standard for terminal sterilization of pharmaceutical liquid preparations \u2014 ophthalmic solutions, irrigation fluids, parenteral drugs, and aqueous-based injectables are routinely subjected to steam sterilization cycles at 121\u00b0C for a minimum of 15 minutes (F\u2080 \u2265 8) or 134\u00b0C for shorter cycles, depending on the product and its sterility assurance level requirement. The container that holds these products through that sterilization cycle must do more than survive the thermal stress: it must emerge dimensionally stable, chemically unchanged, and sealed to the sterility standard the regulatory authority has approved. Glass has traditionally fulfilled this role, but polypropylene \u2014 processed correctly \u2014 offers a compelling combination of autoclave-survivability, lower weight, reduced breakage risk in hospital settings, and compatibility with the precision one-step injection stretch blow moulding machine production process that pharmaceutical container manufacturers need to satisfy their GMP quality management requirements.<\/p>\n

This guide examines how the injection stretch blow moulding machine \u2014 in its one-step ISBM configuration \u2014 produces PP pharmaceutical bottles capable of withstanding autoclave sterilization cycles, why PP is the correct material for this application, what machine architecture is required, and how producers across different global markets can meet the regulatory requirements that govern pharmaceutical primary packaging manufactured on these systems.<\/p>\n<\/div>\n

<\/p>\n

\"Injection<\/div>\n

<\/p>\n

\n

1. Why Polypropylene Is the Material of Choice for Autoclave-Sterilized Pharmaceutical Bottles<\/h2>\n

Polypropylene (PP) occupies a unique position among thermoplastic packaging materials for pharmaceutical applications because it is the only commodity thermoplastic with a heat deflection temperature consistently above the 121\u00b0C steam sterilization threshold. The melting point of standard isotactic PP ranges from 160\u00b0C to 168\u00b0C depending on crystallinity, and its heat deflection temperature at 0.46 MPa load is typically 100\u2013115\u00b0C for homopolymer grades \u2014 sufficient to maintain dimensional stability through a 121\u00b0C\/15-min autoclave cycle when the container is appropriately designed and the PP grade is correctly selected. No other thermoplastic processed on an injection stretch blow moulding machine at standard production volumes can make this claim: PET begins to deform above 65\u00b0C in its amorphous form; PETG softens above 80\u00b0C; even PC begins to lose dimensional precision above 130\u00b0C under sustained steam pressure.<\/p>\n

Beyond thermal stability, PP offers the chemical inertness profile that pharmaceutical primary packaging demands. Homopolymer PP does not leach plasticizers \u2014 there are none \u2014 and its extractable and leachable (E&L) profile is among the lowest of any thermoplastic packaging material. For aqueous pharmaceutical preparations, PP shows no measurable drug adsorption for most active pharmaceutical ingredients. It is approved for pharmaceutical packaging contact under USP Class VI testing, ISO 15223, and the European Pharmacopoeia’s plastics container monographs (Ph. Eur. 3.1.6 for PP). These approvals reflect decades of regulatory precedent for PP in pharmaceutical application, making it a well-characterised material from a regulatory submission standpoint \u2014 an advantage that matters when preparing the Container Closure System section of a new drug application.<\/p>\n\n\n\n\n\n\n\n\n\n\n
Property<\/th>\nPP (Homopolymer)<\/th>\nHUISDIER<\/th>\nPETG<\/th>\npc<\/th>\n<\/tr>\n<\/thead>\n
Melting point (\u00b0C)<\/td>\n160\u2013168<\/td>\n245\u2013265<\/td>\n~210\u2013225 (range)<\/td>\n225\u2013250<\/td>\n<\/tr>\n
Autoclave 121\u00b0C survivability<\/td>\nYes (dimensionally stable)<\/td>\nNo (deforms above 65\u201370\u00b0C)<\/td>\nNo (softens above 80\u00b0C)<\/td>\nMarginal (some grades)<\/td>\n<\/tr>\n
BPA \/ plasticizer content<\/td>\nNone<\/td>\nNone<\/td>\nNone<\/td>\nBPA concern; not recommended for pharma<\/td>\n<\/tr>\n
Ph. Eur. \/ USP pharmacopoeia approval<\/td>\nPh. Eur. 3.1.6; USP Class VI<\/td>\nPh. Eur. 3.1.15<\/td>\nLimited pharma precedent<\/td>\nBPA disclosure required<\/td>\n<\/tr>\n
Drug adsorption (aqueous)<\/td>\nVery low<\/td>\nLow<\/td>\nLow<\/td>\nLow<\/td>\n<\/tr>\n
Transparency<\/td>\nTranslucent (clarified PP = high clarity)<\/td>\nHigh clarity<\/td>\nGlass-like clarity<\/td>\nCrystal clear<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Clarified PP grades \u2014 homopolymer PP compounded with a nucleating agent and optical clarifier \u2014 achieve light transmission above 85% while retaining the heat stability of standard homopolymer PP. This means that pharmaceutical bottles requiring both autoclave survivability and visual inspection of the contents (inspection for particulates, colour change, and precipitate, as required under EU GMP Annex 1 and USP general chapter <790>) can be produced in clarified PP without the opacity penalty of standard PP. The injection stretch blow moulding machine’s precise barrel temperature control and nano far-infrared heating system are well-matched to clarified PP processing, where melt temperature consistency directly affects the optical quality of the clarifier distribution in the finished bottle wall.<\/p>\n<\/div>\n

<\/p>\n

\n

2. Manufacturing Structure: The One-Step ISBM Machine for Pharmaceutical PP Bottle Production<\/h2>\n

The injection stretch blow moulding machine’s one-step architecture is particularly valuable in pharmaceutical PP bottle production because the process hygiene requirements for primary pharmaceutical packaging demand that the container’s interior surface is never exposed to ambient air, handling, or contamination sources between the moment the PP is injected and the moment the finished bottle is ejected. This is exactly what the one-step ISBM cycle delivers: the preform is formed, conditioned, blown, and ejected without ever leaving the controlled machine environment.<\/p>\n

2.1 Four-Station Process Sequence for PP Pharmaceutical Bottles<\/h3>\n

The 4-station configuration is the appropriate platform for autoclave-grade pharmaceutical PP bottles. PP’s wider processing window compared to PET means that the temperature conditioning station at Station 2 plays a different role than it does for PETG cosmetics: rather than preventing crystallisation-induced hazing, it ensures that the PP preform reaches the correct temperature for stretch blowing without overheating the clarifier compound (which can lose clarity above a certain temperature) and without insufficient heating (which produces incomplete shoulder formation in thick-wall pharmaceutical vial formats). This active conditioning step also manages the crystallinity profile in the preform wall, which affects both the mechanical behaviour during autoclave cycling and the long-term stress cracking resistance of the finished bottle under storage conditions.<\/p>\n

\n
\n
01<\/div>\n

Injectie<\/strong><\/p>\n

Pharmaceutical-grade PP (with clarifier if required) injected at precisely controlled melt temperature. Neck finish \u2014 thread form, sealing surface \u2014 formed to injection tolerances. Shot weight consistent across all cavities via servo injection control.<\/p>\n<\/div>\n

\n
02<\/div>\n

Temperature Conditioning<\/strong><\/p>\n

PP preform temperature profile actively managed. Critical for pharmaceutical PP: ensures uniform stretch without disrupting clarifier distribution or inducing excessive crystallinity that reduces bottle flexibility under autoclave pressure cycling.<\/p>\n<\/div>\n

\n
03<\/div>\n

Stretch Blow Moulding<\/strong><\/p>\n

Stretch rod and 2.0\u20133.5 MPa blow air develop biaxial orientation in the PP wall. Orientation in PP improves impact resistance, clarity, and autoclave dimensional stability \u2014 the oriented wall is stiffer and more resistant to the deformation forces of steam pressure.<\/p>\n<\/div>\n

\n
04<\/div>\n

Ejection<\/strong><\/p>\n

Bottles automatically removed with no manual contact. Critical for pharmaceutical GMP: no surface contamination, no operator-introduced particulates, no handling marks. Consistent ejection timing prevents over-cooling that could stress the oriented PP structure.<\/p>\n<\/div>\n<\/div>\n

2.2 Key Mechanical Sub-Systems for Pharmaceutical PP Processing<\/h3>\n

Several sub-systems within the spuitrekblaasvormmachine<\/a> architecture have specific relevance to pharmaceutical PP bottle production quality:<\/p>\n

\n
\n

Nano Far-Infrared Heating Ring<\/h4>\n

Nano far-infrared heating on the screw and barrel provides the stable, zone-specific temperature control that PP processing requires. PP’s wider processing window (typically 200\u2013240\u00b0C for bottle-grade homopolymer) means that barrel temperature stability is achievable, but the heating system must respond quickly to changes in shot weight or ambient conditions to maintain melt quality consistency.<\/p>\n<\/div>\n

\n

Servo Drive Precision<\/h4>\n

Pharmaceutical PP bottle production requires injection weight consistency of \u00b10.5 g or better across production runs to maintain wall thickness uniformity within specification. The servo injection drive’s position feedback loop holds the injection profile to within a fraction of a percent of set point, eliminating the hydraulic pressure drift that causes weight variation in non-servo systems.<\/p>\n<\/div>\n

\n

Parker High-Pressure Valve<\/h4>\n

Consistent blow pressure delivery is essential for dimensional repeatability in pharmaceutical PP bottles, where container volume specification relates directly to dosing accuracy. The Parker high-pressure valves fitted across the machine range deliver the 2.0\u20133.5 MPa blow pressure with valve-to-valve repeatability appropriate for high-precision pharmaceutical container production.<\/p>\n<\/div>\n

\n

PLC Process Data Logging<\/h4>\n

The Inovance or MIRLE PLC system logs injection pressure, barrel temperature, cycle time, and conditioning parameters for every production cycle. This data logging capability is a GMP requirement for pharmaceutical primary packaging production \u2014 batch records must demonstrate process consistency and support the traceability chain from raw material through finished container to filled drug product.<\/p>\n<\/div>\n<\/div>\n<\/div>\n

<\/p>\n

\"Injection<\/div>\n

<\/p>\n

\n

3. PP Material System: Grades, Additives, and Autoclave Performance<\/h2>\n

Not all PP grades are equal in their suitability for autoclave-sterilized pharmaceutical bottles. The resin selection must balance thermal stability through the autoclave cycle, extractable and leachable (E&L) profile appropriate for the drug product, mechanical properties sufficient for the bottle’s end-use requirements (fill, seal, labelling, distribution, and hospital dispensing), and optical clarity appropriate for particulate inspection of the filled product.<\/p>\n

3.1 PP Grade Selection Criteria<\/h3>\n

For autoclave-grade pharmaceutical bottles on an injection stretch blow moulding machine, the following PP grade categories are relevant:<\/p>\n\n\n\n\n\n\n\n\n
PP Grade<\/th>\nAutoclave Stability<\/th>\nClarity<\/th>\nE&L Profile<\/th>\nBest Pharmaceutical Application<\/th>\n<\/tr>\n<\/thead>\n
PP Homopolymer (standard)<\/strong><\/td>\nExcellent<\/td>\nTranslucent<\/td>\nVery low<\/td>\nIrrigation solution bottles, opaque pharmaceutical bottles where visual inspection not required<\/td>\n<\/tr>\n
PP Homopolymer (clarified)<\/strong><\/td>\nExcellent<\/td>\nHigh clarity (85\u201390% T)<\/td>\nLow (clarifier selected for pharma approval)<\/td>\nOphthalmic solution bottles, injectable solution vials requiring particulate inspection through the wall<\/td>\n<\/tr>\n
PP Random Copolymer<\/strong><\/td>\nGood (lower heat deflection than homopolymer)<\/td>\nBetter than homopolymer<\/td>\nVery low<\/td>\nOral liquid medicine bottles, paediatric syrups; improved low-temperature impact versus homopolymer<\/td>\n<\/tr>\n
PP Medical Grade (DMF\/DMF registered)<\/strong><\/td>\nExcellent<\/td>\nVaries<\/td>\nQualified per USP Class VI, ISO 10993, Ph. Eur.<\/td>\nAny pharmaceutical primary packaging requiring regulatory submission support; E&L data typically provided by resin supplier’s Drug Master File<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

3.2 Autoclave Cycle Performance: What Happens to PP at 121\u00b0C<\/h3>\n

During a pharmaceutical autoclave cycle at 121\u00b0C \/ 2.2 bar saturated steam for 15 minutes, a correctly designed and produced PP bottle undergoes a limited, controlled response. PP’s crystalline regions \u2014 which form the structural backbone of the material \u2014 are unaffected at 121\u00b0C because they melt at 160\u2013168\u00b0C. The amorphous regions between crystallites soften slightly, allowing limited molecular relaxation, but the crystalline network holds the overall bottle geometry. The practical consequence is that properly designed PP pharmaceutical bottles may show a slight reduction in volume (0.5\u20131.5% is acceptable in most pharmacopoeia specifications) and a slight increase in wall haze (particularly in clarified PP grades where the clarifier compound’s optical performance changes slightly above 100\u00b0C). These changes must be characterised during container qualification and shown to be within the limits specified in the container closure system section of the drug registration dossier.<\/p>\n

The wall thickness design of the PP bottle has a significant influence on autoclave survivability. Walls that are too thin (below 0.4 mm in the body) may deform under the steam pressure differential if the bottle interior is not filled with liquid during sterilization. Pharmaceutical PP bottles are typically sterilized filled \u2014 the liquid acts as an internal pressure support \u2014 but empty bottle-autoclave cycling (for steam sterilization of packaging before fill) requires wall thickness and geometry designed for the external steam pressure loading without internal support. Machine-level control of wall thickness (achievable to \u00b110% through servo injection and blow pressure control on the injection stretch blow moulding machine) is therefore a direct quality factor in autoclave survivability of the finished container.<\/p>\n<\/div>\n

<\/p>\n

\n

4. Recommended Machine for Pharmaceutical PP Bottle Production<\/h2>\n

For pharmaceutical PP bottle production covering ophthalmic solutions (5\u201330 ml), oral liquid medicines (50\u2013500 ml), and irrigation fluid bottles (100\u20131,000 ml), the 4-station HGYS150-V4 is a well-matched platform. Its temperature conditioning station enables the controlled PP preform thermal management that autoclave-grade bottle quality demands, while its ASB-12M mold compatibility allows producers transitioning from legacy asb injection molding machine platforms to validate the new machine using existing mold tooling before investment in new pharmaceutical container designs.<\/p>\n

\n
\"EP-HGYS150-V4<\/div>\n
\n

EP-HGYS150-V4 \u00b7 4-Station One-Step Injection Stretch Blow Moulding Machine<\/h4>\n

Applicable Material:<\/strong> PET \/ PETG \/ PP (with appropriate screw configuration)<\/p>\n

Control System:<\/strong> 3 servo pump systems; Inovance \/ MIRLE PLC<\/p>\n

Servo Motor Power:<\/strong> 43.2 KW (Inovance \/ WEICHI)<\/p>\n

Injection Clamping Force:<\/strong> 150 KN<\/p>\n

Blowing Clamping Force:<\/strong> 200 KN (single side)<\/p>\n

Heating Power:<\/strong> 10 KW (nano far-infrared heating ring)<\/p>\n

Blowing Air Pressure:<\/strong> 2.0\u20133.5 MPa<\/p>\n

Screw Diameter Options:<\/strong> 40 \/ 50 \/ 55 \/ 60 mm<\/p>\n

Conditioning Core Stroke:<\/strong> 250 mm | Conditioning Barrel Stroke:<\/strong> 230 mm<\/p>\n

Upper Mold Stroke:<\/strong> 250 mm | Lower Mold Stroke:<\/strong> 205 mm<\/p>\n

Take-out Stroke:<\/strong> 170 mm | Blow Core Stroke:<\/strong> 250 mm<\/p>\n

Max Cavities:<\/strong> 8 | Max Bottle Volume:<\/strong> 2500 ml<\/p>\n

Machine Size (L\u00d7W\u00d7H):<\/strong> 4,200 \u00d7 1,400 \u00d7 2,900 mm<\/p>\n

Machine Weight:<\/strong> 6 T | Total Power:<\/strong> 53.2 KW<\/p>\n

Mold Compatibility:<\/strong> Compatibel met ASB-12M mallen<\/p>\n

Lead Screw:<\/strong> NSK Japan | High-Pressure Valve:<\/strong> Parker USA<\/p>\n

Cooling Water Pressure:<\/strong> 0.4\u20130.6 MPa | Oil Cooler Water Pressure:<\/strong> 0.3\u20130.4 MPa<\/p>\n

Voltage:<\/strong> 370\u2013400 V | Oil Tank Volume:<\/strong> 300 L<\/p>\n<\/div>\n<\/div>\n<\/div>\n

<\/p>\n

\n

5. GMP Quality Requirements for Pharmaceutical PP Bottle Production<\/h2>\n

Pharmaceutical primary packaging production is governed by Good Manufacturing Practice (GMP) requirements that are substantially more demanding than the quality management systems applied to cosmetic or food-grade container production. When an injection stretch blow moulding machine is used to produce PP bottles that will be classified as pharmaceutical primary packaging \u2014 meaning they will be in direct contact with a medicinal product \u2014 the machine, its operating environment, and the production process must all satisfy GMP requirements as laid down by the relevant regulatory authority in each market.<\/p>\n

5.1 Equipment Qualification: IQ, OQ, PQ<\/h3>\n

The three-stage equipment qualification framework \u2014 Installation Qualification (IQ), Operational Qualification (OQ), and Performance Qualification (PQ) \u2014 applies to any machine used in pharmaceutical primary container production under GMP. The injection stretch blow moulding machine must be qualified through this protocol before it can be used in validated commercial production. IQ confirms that the machine is installed correctly (utilities connected to specification, safety systems functional, all components as specified in the purchase order). OQ confirms that the machine performs to its engineering specification across its operating range \u2014 injection pressure, temperature, cycle time, and dimensional output. PQ confirms that the machine consistently produces containers meeting their pharmaceutical specification across a defined number of production batches. The Inovance or MIRLE PLC data logging system provides the continuous process parameter records that PQ monitoring requires, and the machine supplier should provide an IQ\/OQ documentation template as part of the standard supply package for pharmaceutical buyers.<\/p>\n

5.2 Cleanroom Environment and Particulate Control<\/h3>\n

The production environment for pharmaceutical PP bottle manufacture must satisfy GMP environmental monitoring requirements. The exact classification depends on the drug product and fill\/finish process, but most pharmaceutical container production for sterile products is conducted in ISO Class 7 or Class 8 clean room environments, with the machine itself potentially located in a classified zone or isolated from the cleanroom through a transfer hatch system. The one-step injection stretch blow moulding machine’s sealed production cycle \u2014 where the container interior is never exposed to ambient air between injection and ejection \u2014 is a process hygiene advantage in this context: the primary contamination pathway for the container interior is eliminated at the machine level.<\/p>\n

5.3 Container Closure System Validation<\/h3>\n

The finished PP bottle, together with its closure (stopper, cap, or seal), constitutes the Container Closure System (CCS) that must be validated under ICH Q1A shelf life guidelines and the pharmacopoeia requirements applicable in the target market. For autoclave-sterilized products, the CCS must demonstrate container integrity maintenance \u2014 typically by integrity testing before and after autoclave cycling using methods such as headspace gas analysis, vacuum decay, or dye ingress testing. The dimensional consistency that the injection stretch blow moulding machine delivers \u2014 particularly neck thread accuracy and sealing surface geometry, both formed at the injection station \u2014 directly determines the CCS’s ability to pass these integrity tests consistently across container lots.<\/p>\n<\/div>\n

<\/p>\n

\n

6. Global Regulatory Frameworks for Pharmaceutical PP Bottle Production<\/h2>\n

Pharmaceutical primary packaging \u2014 including PP bottles produced on an injection stretch blow moulding machine \u2014 is among the most heavily regulated categories of industrial packaging. Each major pharmaceutical market maintains its own regulatory framework governing material safety, container qualification, GMP compliance for the manufacturer, and the machine safety requirements for the production equipment. The following overview covers the major markets for pharmaceutical PP bottle production.<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n
Market<\/th>\nPP Container Material Standard<\/th>\nGMP \/ Manufacturing Regulation<\/th>\nMachine Compliance Requirement<\/th>\n<\/tr>\n<\/thead>\n
Europese Unie<\/strong><\/td>\nPh. Eur. 3.1.6 (PP containers); Ph. Eur. 3.2.2 (plastic containers for aqueous preparations for infusion); EU GMP Annex 1 (sterile medicinal products)<\/td>\nEU GMP Guidelines (EudraLex Vol. 4); Annex 15 (qualification and validation); GMP certification of container manufacturer for supply to pharma industry<\/td>\nCE marking under Machinery Directive 2006\/42\/EC; IQ\/OQ\/PQ qualification protocol; ISPM 15 export crating<\/td>\n<\/tr>\n
United Kingdom<\/strong><\/td>\nBritish Pharmacopoeia (BP) retained Ph. Eur. monographs; MHRA Orange Guide (Rules and Guidance for Pharmaceutical Manufacturers)<\/td>\nMHRA GMP inspectorate applies UK GMP equivalent to EU GMP Vol. 4; Annex 15 qualification requirements retained in UK law<\/td>\nUKCA marking post-Brexit; Supply of Machinery (Safety) Regulations 2008; IQ\/OQ template documentation<\/td>\n<\/tr>\n
United States<\/strong><\/td>\nUSP <661> Plastic Packaging Systems for Pharmaceutical Use; USP <87>\/<88> (biological reactivity, Class VI testing); USP <790> (visible particulates in injections)<\/td>\nFDA 21 CFR Parts 210 and 211 (cGMP for finished pharmaceuticals); FDA 21 CFR Part 211.94 (drug product containers and closures); FDA guidance on Container Closure Systems (1999, revised)<\/td>\nOSHA 29 CFR 1910.212 machine guarding; NEC electrical compliance; Equipment qualification (IQ\/OQ\/PQ) per FDA 21 CFR Part 211<\/td>\n<\/tr>\n
Australia<\/strong><\/td>\nTGA Code of GMP (based on PIC\/S GMP Guide PE009); Australian Regulatory Guidelines for Prescription Medicines (ARGPM) for CCS requirements; BP\/Ph. Eur. material monographs accepted<\/td>\nTGA PIC\/S GMP audit for pharmaceutical manufacturers; container manufacturer qualification required in CTD Module 3 of drug registration<\/td>\nAS\/NZS 3000 electrical connection; state WorkSafe machinery registration; ISPM 15 strictly enforced<\/td>\n<\/tr>\n
Japan<\/strong><\/td>\nJapanese Pharmacopoeia (JP) General Notice 1 (containers); JP <7.02> Plastic containers for aqueous preparations; PMDA guidance on CCS<\/td>\nMinisterial Ordinance No. 179 (GMP for pharmaceutical products); PMDA Drug Master File (DMF) for packaging materials<\/td>\nIndustrial Safety and Health Act for machinery; CE equivalent documentation accepted; IQ\/OQ\/PQ per PMDA expectations<\/td>\n<\/tr>\n
South Korea<\/strong><\/td>\nKorean Pharmacopoeia (KP) container monographs; MFDS (Ministry of Food and Drug Safety) guidelines for pharmaceutical packaging; K-REACH substance restrictions<\/td>\nMFDS GMP requirements (aligned with PIC\/S); container manufacturer qualification in drug product registration dossier<\/td>\nKC Mark for electrical components; MOEL industrial safety machinery registration; IQ\/OQ template required for pharma buyers<\/td>\n<\/tr>\n
Brazili\u00eb<\/strong><\/td>\nBrazilian Pharmacopoeia (FB) container monographs; ANVISA RDC 301\/2019 (GMP for pharmaceutical products); ANVISA RDC 204\/2017 (pharmaceutical packaging)<\/td>\nANVISA GMP certification (CBPF) required for pharmaceutical manufacturers and container manufacturers supplying regulated products<\/td>\nNR-12 machinery safety; INMETRO conformity for electrical components; RETIE; ISPM 15<\/td>\n<\/tr>\n
India<\/strong><\/td>\nIndian Pharmacopoeia (IP) container standards; Drugs and Cosmetics Act 1940 and Rules 1945 (Schedule M for GMP); CDSCO guidance on pharmaceutical packaging<\/td>\nCDSCO GMP inspections (aligning progressively with PIC\/S); container qualification in drug product dossier for registration<\/td>\nBureau of Indian Standards (BIS) electrical equipment standards; machinery CE marking generally accepted by CDSCO; ISPM 15 required<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

A significant regulatory development relevant to pharmaceutical PP bottle production across all major markets is the PIC\/S (Pharmaceutical Inspection Co-operation Scheme) harmonisation of GMP standards. PIC\/S currently has 55 participating authorities including FDA, EMA, TGA, MFDS, ANVISA (observer status), and Health Canada. Machine suppliers providing injection stretch blow moulding machines to PIC\/S-member country pharmaceutical manufacturers can use the EU GMP equipment qualification framework (IQ\/OQ\/PQ per EU GMP Annex 15) as a baseline that is accepted by most PIC\/S members, significantly reducing the regulatory adaptation burden when supplying machines across multiple markets.<\/p>\n<\/div>\n

<\/p>\n

\"Injection<\/div>\n

<\/p>\n

\n

7. Designing PP Pharmaceutical Bottles for Autoclave Compatibility<\/h2>\n

Container design for autoclave-sterilized pharmaceutical bottles requires explicit consideration of the thermal and mechanical stresses of the autoclave cycle at every feature of the container geometry. The injection stretch blow moulding machine produces containers to specifications set at the mold design stage, so autoclave compatibility must be designed in at the mold engineering phase \u2014 not retrofitted after container qualification reveals a weakness.<\/p>\n

7.1 Wall Thickness and Geometry<\/h3>\n

Minimum wall thickness for autoclave-compatible PP bottles is typically 0.5\u20130.8 mm in the body section for filled-bottle sterilization, and 0.8\u20131.2 mm for containers that may be autoclaved empty. The bottom dome geometry \u2014 particularly the base panel radius and its transition to the sidewall \u2014 must be designed to distribute autoclave steam pressure loading without inducing point-stress concentrations that could cause stress cracking during or after sterilization. Flat bases are generally avoided in autoclave PP bottles in favour of champagne-base or convex-dome profiles that are inherently stronger under external pressure loading.<\/p>\n

7.2 Neck Finish for Autoclave-Compatible Sealing<\/h3>\n

The closure system for autoclave-sterilized pharmaceutical bottles must maintain hermetic integrity through the thermal cycle \u2014 including the rapid temperature transitions of autoclave loading, sterilization hold, and cooling. For PP bottles sealed with PP closures, the neck thread form and sealing surface must be designed to accommodate the differential thermal expansion between the closure and the bottle while maintaining adequate sealing force throughout the temperature range. The injection stretch blow moulding machine’s injection-station neck formation provides the dimensional precision (thread diameter to \u00b10.05 mm) that consistent sealing performance across container lots requires.<\/p>\n\n\n\n\n\n\n\n\n\n
Application<\/th>\nVolume Range (ml)<\/th>\nPP Grade<\/th>\nAutoclave Cycle<\/th>\nMachine Platform<\/th>\n<\/tr>\n<\/thead>\n
Ophthalmic solution<\/td>\n5\u201330<\/td>\nClarified homopolymer PP<\/td>\n121\u00b0C \/ 15 min (F\u2080 \u2265 8)<\/td>\nHGY50-V3-EV (3-station, up to 6 cavities)<\/td>\n<\/tr>\n
Oral liquid medicine<\/td>\n50\u2013250<\/td>\nPP random copolymer or clarified homopolymer<\/td>\n121\u00b0C \/ 15 min (terminal sterilization where applicable)<\/td>\nHGYS150-V4 (4-station, 4\u20138 cavities)<\/td>\n<\/tr>\n
Injectable solution vial<\/td>\n20\u2013100<\/td>\nMedical-grade clarified homopolymer PP (USP Class VI)<\/td>\n121\u00b0C \/ 15 min (typical); 134\u00b0C available for higher F\u2080 requirement<\/td>\nHGYS150-V4 (4-station, temperature conditioning required)<\/td>\n<\/tr>\n
Irrigation fluid bottle<\/td>\n100\u20131,000<\/td>\nPP homopolymer (semi-transparent or translucent)<\/td>\n121\u00b0C \/ 15\u201330 min<\/td>\nHGYS200-V4 or HGY250-V4 (4-station, higher clamping force for larger formats)<\/td>\n<\/tr>\n
Paediatric medicine bottle<\/td>\n50\u2013200<\/td>\nPP random copolymer (improved low-temperature impact)<\/td>\n121\u00b0C \/ 15 min or aseptic fill (no terminal sterilization)<\/td>\nHGYS150-V4 or HGY50-V3-EV depending on format size<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n

<\/p>\n

\n

8. One-Step ISBM vs. Two-Step Blow Moulding for Pharmaceutical PP Bottles<\/h2>\n

The process hygiene comparison between one-step and two-step production is more consequential in pharmaceutical packaging than in almost any other application category. The two-step process \u2014 where PP preforms are injection-moulded, cooled, stored, transported, and then reheated for blow moulding \u2014 introduces a preform storage phase during which the preform’s interior and exterior surfaces are exposed to the production environment. In a pharmaceutical GMP context, this exposure requires the preform storage area to be included in the environmental monitoring programme, the preform transfer to be conducted under controlled conditions, and the preform washing or inspection steps to be validated. Each of these requirements represents regulatory compliance burden and potential contamination risk that the one-step injection stretch blow moulding machine architecture eliminates.<\/p>\n

The one-step machine cycle takes the PP from melt to finished bottle interior surface without any environmental exposure at any point. The container’s interior surface \u2014 the face that will be in contact with the pharmaceutical preparation \u2014 is formed inside the injection mold cavity, conditioned, and blow-moulded in a sealed sequence. The only environmental exposure of the container interior occurs when the bottle exits the machine’s ejection station, at which point it immediately enters the clean-room transfer or primary packaging line. For pharmaceutical producers under GMP, this process architecture represents a fundamental risk reduction that is recognised in the EU GMP Annex 1 rationale for closed-process design in sterile manufacturing environments.<\/p>\n<\/div>\n

<\/p>\n

\n

Over ons<\/h2>\n

With more than two decades of experience developing one-step injection stretch blow moulding machine platforms, our engineering team has accumulated substantial practical knowledge of pharmaceutical primary packaging applications \u2014 from ophthalmic solution bottles requiring clarified PP and autoclave survivability through to oral liquid medicine containers and irrigation fluid bottles requiring validated Container Closure System performance. Our production facility, covering more than 20,000 square metres of precision machining and assembly floor, manufactures ISBM machines deployed in pharmaceutical packaging plants across Europe, Japan, Australia, South Korea, India, and South America.<\/p>\n

Machines supplied to pharmaceutical packaging producers come with IQ\/OQ documentation templates as standard, structured to be compatible with EU GMP Annex 15, USP, JP, and PIC\/S qualification framework requirements. The Inovance or MIRLE PLC data logging system supports GMP batch record requirements. Core components \u2014 Parker high-pressure valves, NSK Japan lead screws, Yaskawa and Inovance servo systems \u2014 are sourced from globally recognised suppliers whose performance specifications suit the quality-critical pharmaceutical application environment. CE marking documentation under Machinery Directive 2006\/42\/EC is provided as standard for EU-market machines; UKCA, KC, and other market-specific certifications are available on request at the order stage.<\/p>\n

Workshop<\/h3>\n
\n
\"Workshopweergave
\n\"Workshopweergave
\n\"Workshopweergave
\n\"Workshopweergave<\/div>\n<\/div>\n<\/div>\n

<\/p>\n

\n

Related Equipment for Pharmaceutical PP Bottle Production Lines<\/h2>\n

Consistent, GMP-compliant output from an injection stretch blow moulding machine in pharmaceutical PP bottle production depends not only on the machine but on the auxiliary systems that support it. Two systems have direct influence on product quality and GMP compliance in pharmaceutical PP bottle production environments.<\/p>\n

\n
\"Oil-free<\/p>\n

Oil-Free Air Compressor<\/a><\/h3>\n

In pharmaceutical PP bottle production, the requirement for oil-free blow air is not optional \u2014 it is a GMP imperative. Oil aerosol depositing on the interior surface of a pharmaceutical container constitutes an elemental impurity and a potential extractable that must be declared and justified in the drug product’s regulatory submission. An oil-free high-pressure compressor<\/a> eliminates this contamination pathway entirely, delivering clean compressed air at 2.0\u20133.5 MPa without the oil contamination risk associated with lubricated reciprocating compressors. For pharmaceutical GMP compliance, the compressor should carry a validated oil-free designation from the manufacturer with supporting analytical data, and the compressed air supply should include in-line oil-detection monitoring where the regulatory environment requires it.<\/p>\n<\/div>\n

\"Mould<\/p>\n

Temperatuurregelaar voor de matrijs<\/h3>\n

Blow mold temperature consistency is a critical process parameter in pharmaceutical PP bottle production \u2014 one that must be defined, controlled, and recorded as part of the validated process. For PP pharmaceutical containers, the cooling rate during and after blow moulding influences the degree of crystallinity in the bottle wall, which in turn affects the autoclave survivability profile and the stress cracking resistance over the container’s shelf life. A precision mould temperature controller maintaining coolant temperature within \u00b11\u00b0C of the validated setpoint produces consistent crystallinity across production batches, supporting batch-to-batch reproducibility in the container qualification record. For GMP pharmaceutical production, the mould temperature controller should be calibrated on a schedule consistent with the validated process and the calibration records maintained as part of the equipment qualification documentation. Including the mould temperature controller in the same procurement as the injection stretch blow moulding machine simplifies system commissioning and the IQ verification step.<\/p>\n<\/div>\n<\/div>\n<\/div>\n

<\/p>\n

\n

Discuss Your Pharmaceutical PP Bottle Production Requirements<\/h2>\n

Whether you are specifying an injection stretch blow moulding machine for a new pharmaceutical PP container line, replacing legacy ASB or AOKI equipment, or developing containers for a new autoclave-sterilized drug product, our pharmaceutical packaging application team can review your container specification and advise on the appropriate machine configuration, PP grade, and IQ\/OQ qualification support.<\/p>\n<\/div>\n

<\/p>\n

\n

Veelgestelde vragen<\/h2>\n
\nQ1. Which injection stretch blow moulding machine model is best for producing autoclave-grade clarified PP ophthalmic bottles in Europe under EU GMP?<\/summary>\n
\n

For clarified PP ophthalmic bottles (5\u201330 ml) produced under EU GMP, the HGYS150-V4 four-station injection stretch blow moulding machine is the recommended platform. The temperature conditioning station manages the PP preform thermal profile precisely, ensuring uniform wall thickness \u2014 essential for ophthalmic containers where particulate inspection through the bottle wall is a regulatory requirement under EU GMP Annex 1. The machine’s CE marking documentation (Machinery Directive 2006\/42\/EC) is provided as standard, and IQ\/OQ documentation templates structured to EU GMP Annex 15 are available. For the EU pharmaceutical market, the PP container material must comply with Ph. Eur. 3.1.6 (polypropylene containers for parenteral preparations and for ophthalmic preparations), and the clarifier compound must appear in the resin supplier’s EU-compliant compound declaration. The machine’s PLC data logging supports the batch record requirements of EU GMP Vol. 4 Chapter 4.<\/p>\n<\/div>\n<\/details>\n

\nHow does the injection stretch blow moulding machine process help pharmaceutical packaging manufacturers meet USP Class VI testing requirements for PP containers?<\/summary>\n
\n

USP Class VI testing is a biological safety evaluation that tests plastic materials for systemic toxicity, intracutaneous reactivity, and implantation reaction. It is not a test of the finished container’s dimensional or functional performance \u2014 it is a test of the polymer itself. Passing USP Class VI requires specifying a PP resin grade that the resin supplier has already tested and certified to USP <88> requirements, which most pharmaceutical-grade PP homopolymer grades sold through established resin suppliers are. The injection stretch blow moulding machine’s role in USP Class VI compliance is to process the PP within the validated temperature and shear range that does not degrade the polymer \u2014 because thermal or shear degradation of PP can produce degradation products that would not be present in the resin supplier’s original USP Class VI test samples. The machine’s barrel temperature stability and servo-controlled injection shear rate management are therefore supporting factors in maintaining the USP Class VI compliance of the finished container through the production process.<\/p>\n<\/div>\n<\/details>\n

\nWhat IQ\/OQ documentation does an injection stretch blow moulding machine supplier provide for pharmaceutical buyers in Australia seeking TGA GMP compliance?<\/summary>\n
\n

For pharmaceutical container manufacturers in Australia operating under TGA GMP (PIC\/S PE009-based), the IQ\/OQ documentation package for an injection stretch blow moulding machine should include: Installation Qualification protocol confirming utility connections (electrical supply, cooling water, compressed air) meet machine specification; calibration records for temperature sensors, pressure transmitters, and servo encoders; software validation records for the PLC control system confirming version-controlled operation; OQ test results covering injection pressure profiles, barrel temperature stability, cycle time, and container dimensional output across the machine’s qualified operating range; and a Summary Report confirming all IQ\/OQ acceptance criteria were met. The TGA’s GMP guidance for packaging manufacturers follows PIC\/S, which recognises EU GMP Annex 15 as the qualification framework, so machine supplier IQ\/OQ templates structured to EU GMP Annex 15 format are directly usable for TGA compliance purposes. ISPM 15 crating compliance must be confirmed before shipment, as Australian Biosecurity (DAFF) enforces this strictly.<\/p>\n<\/div>\n<\/details>\n

\nHow does the one-step injection stretch blow moulding machine maintain process cleanliness for GMP pharmaceutical PP bottle production?<\/summary>\n
\n

The one-step injection stretch blow moulding machine maintains pharmaceutical GMP cleanliness through its closed-cycle architecture: the PP preform’s interior surface is formed inside the injection mold cavity at Station 1, moves to temperature conditioning at Station 2 without ever being removed from the machine, is blow-moulded at Station 3, and ejected at Station 4 \u2014 all without the preform or container being exposed to ambient air, operator contact, or environmental contamination between injection and ejection. This process closure eliminates the primary contamination risk that two-step processes carry through the preform storage and transfer phase. For pharmaceutical producers, this means that the container interior contamination control strategy can focus on the ejection and downstream transfer rather than managing contamination across a preform storage and reheating cycle that would require extensive environmental monitoring and preform handling controls under EU GMP and FDA cGMP requirements.<\/p>\n<\/div>\n<\/details>\n

\nWhich PP grade should pharmaceutical packaging suppliers in Japan specify for injectable solution bottles meeting Japanese Pharmacopoeia requirements?<\/summary>\n
\n

For injectable solution bottles in Japan meeting Japanese Pharmacopoeia (JP) requirements under JP General Notice 1 and JP <7.02> (plastic containers for aqueous preparations), the PP grade should be a homopolymer or random copolymer grade carrying either the resin supplier’s own JP compliance declaration or a Drug Master File (DMF) filed with PMDA that covers the specific grade and compound. In practice, the major PP resin suppliers active in the Japanese pharmaceutical market maintain PMDA DMFs for their pharmaceutical-grade PP compounds, and specifying from the DMF-registered compound list is the most straightforward compliance path. Clarified homopolymer PP is appropriate for injectable solution bottles requiring visual particulate inspection; non-clarified homopolymer is acceptable for irrigation fluids where transparency is not a primary specification. The injection stretch blow moulding machine’s barrel temperature should be set within the PP supplier’s processing recommendation for the specific pharmaceutical-grade compound to avoid IV degradation that could introduce degradation products not covered by the resin supplier’s DMF submission.<\/p>\n<\/div>\n<\/details>\n

\nWhat is the best injection stretch blow moulding machine configuration for producing PP irrigation solution bottles in Brazil under ANVISA GMP requirements?<\/summary>\n
\n

For PP irrigation solution bottles (100\u20131,000 ml) produced in Brazil under ANVISA RDC 301\/2019 GMP requirements, the HGYS200-V4 or HGY250-V4 four-station injection stretch blow moulding machine is appropriate depending on the target volume and cavity count. The higher injection clamping force (300 KN) of these models accommodates the larger preform weight required for 500\u20131,000 ml irrigation containers. For ANVISA GMP compliance, the machine qualification (IQ\/OQ\/PQ) documentation must be prepared in Portuguese and maintained as part of the facility’s GMP documentation system. The PP resin must comply with ANVISA RDC 204\/2017 for pharmaceutical packaging materials, and the Brazilian Pharmacopoeia (FB) container monograph for plastic containers for aqueous preparations must be referenced in the container specification. For electrical compliance, the machine should be specified for 380 V, 3-phase, 60 Hz (Brazil standard), and INMETRO conformity for electrical sub-assemblies should be confirmed at the order stage. NR-12 machinery safety compliance documentation must be available for the production facility’s operating permit inspection.<\/p>\n<\/div>\n<\/details>\n

\nHow does replacing an asb injection molding machine with a one-step ISBM machine affect the GMP validation programme for a pharmaceutical PP bottle line?<\/summary>\n
\n

Replacing an asb injection molding machine with a one-step injection stretch blow moulding machine in a pharmaceutical production setting constitutes a change to the validated manufacturing process, which under EU GMP, FDA cGMP, and most PIC\/S-equivalent frameworks requires a formal change control assessment. The change control assessment should evaluate whether the container produced on the new machine meets the same specification as the container produced on the legacy machine using the same mold tooling \u2014 which it should, given that several ISBM platforms are designed to accept ASB-12M tooling. The change control package should include: re-IQ\/OQ of the new machine; comparative dimensional data between old and new machine output using the same mold; accelerated stability study demonstrating that the container produced on the new machine performs equivalently to the validated container through autoclave cycling and shelf life; and regulatory change notification to relevant authorities where the machine change constitutes a variation to the marketing authorisation. In most markets, a machine-only change using the same mold, same material, and same container specification qualifies for a minor variation or notification rather than a full new marketing authorisation \u2014 but this should be confirmed with regulatory affairs counsel in each target market.<\/p>\n<\/div>\n<\/details>\n<\/div>\n<\/div>\n

Redacteur: PXY<\/p>","protected":false},"excerpt":{"rendered":"

Pharmaceutical & Medical Packaging \u00b7 Technical Guide A technical guide to the role of the injection stretch blow moulding machine in pharmaceutical PP bottle production \u2014 covering polypropylene’s autoclave compatibility, manufacturing structure, GMP compliance frameworks, and machine selection for pharmaceutical packaging producers worldwide. Autoclave sterilization remains the gold standard for terminal sterilization of pharmaceutical liquid […]<\/p>","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[28],"tags":[],"class_list":["post-729","post","type-post","status-publish","format-standard","hentry","category-pharmaceutical-medical-packaging"],"_links":{"self":[{"href":"https:\/\/onestepblowmachine.com\/nl\/wp-json\/wp\/v2\/posts\/729","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/onestepblowmachine.com\/nl\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/onestepblowmachine.com\/nl\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/onestepblowmachine.com\/nl\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/onestepblowmachine.com\/nl\/wp-json\/wp\/v2\/comments?post=729"}],"version-history":[{"count":2,"href":"https:\/\/onestepblowmachine.com\/nl\/wp-json\/wp\/v2\/posts\/729\/revisions"}],"predecessor-version":[{"id":731,"href":"https:\/\/onestepblowmachine.com\/nl\/wp-json\/wp\/v2\/posts\/729\/revisions\/731"}],"wp:attachment":[{"href":"https:\/\/onestepblowmachine.com\/nl\/wp-json\/wp\/v2\/media?parent=729"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/onestepblowmachine.com\/nl\/wp-json\/wp\/v2\/categories?post=729"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/onestepblowmachine.com\/nl\/wp-json\/wp\/v2\/tags?post=729"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}